Abdel-Hamid, Mona

[["dc.bibliographiccitation.firstpage","1199"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","JAMA Psychiatry"],["dc.bibliographiccitation.lastpage","1210"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Philipsen, Alexandra"],["dc.contributor.author","Jans, Thomas"],["dc.contributor.author","Graf, Erika"],["dc.contributor.author","Matthies, Swantje"],["dc.contributor.author","Borel, Patricia"],["dc.contributor.author","Colla, Michael"],["dc.contributor.author","Gentschow, Laura"],["dc.contributor.author","Langner, Daina"],["dc.contributor.author","Jacob, Christian P."],["dc.contributor.author","Gross-Lesch, Silke"],["dc.contributor.author","Sobanski, Esther"],["dc.contributor.author","Alm, Barbara"],["dc.contributor.author","Schumacher-Stien, Martina"],["dc.contributor.author","Roesler, Michael"],["dc.contributor.author","Retz, Wolfgang"],["dc.contributor.author","Retz-Junginger, Petra"],["dc.contributor.author","Kis, Bernhard"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Heinrich, Viola"],["dc.contributor.author","Huss, Michael"],["dc.contributor.author","Kornmann, Catherine"],["dc.contributor.author","Buerger, Arne"],["dc.contributor.author","Perlov, Evgeniy"],["dc.contributor.author","Ihorst, Gabriele"],["dc.contributor.author","Schlander, Michael"],["dc.contributor.author","Berger, Mathias"],["dc.contributor.author","van Elst, Ludger Tebartz"],["dc.date.accessioned","2018-11-07T09:48:03Z"],["dc.date.available","2018-11-07T09:48:03Z"],["dc.date.issued","2015"],["dc.description.abstract","IMPORTANCE Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood. There is a recognized need to assess the efficacy of psychotherapy in adult ADHD. OBJECTIVE To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (CM) and that of methylphenidate hydrochloride compared with placebo. DESIGN, SETTING, AND PARTICIPANTS Prospective, multicenter, randomized clinical trial of 18- to 58-year-old outpatients with ADHD from 7 German study centers. Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessments occurred in March 2013. INTERVENTIONS Sessions of GPT and CM were held weekly for the first 12 weeks and monthly thereafter (9 months). Patients received either methylphenidate or placebo for 1 year. MAIN OUTCOMES AND MEASURES The primary outcome was the change in the ADHD Index of the Conners Adult ADHD Rating Scale from baseline to the end of the 3-month intensive treatment (blinded observer ratings). Secondary outcomes included ADHD ratings after 1 year, blinded observer ratings using the Clinical Global Impression Scale, and self-ratings of depression. RESULTS Among 1480 prescreened patients, 518 were assessed for eligibility, 433 were centrally randomized, and 419 were analyzed as randomized. After 3 months, the ADHD Index all-group baseline mean of 20.6 improved to adjusted means of 17.6 for GPT and 16.5 for CM, with no significant difference between groups. Methylphenidate (adjusted mean, 16.2) was superior to placebo (adjusted mean, 17.9) (difference, -1.7; 97.5% CI, -3.0 to -0.4; P = .003). After 1 year, treatment effects remained essentially stable. Descriptive analyses showed that methylphenidate was superior to placebo in patients assigned to GPT (difference, -1.7; 95% CI, -3.2 to -0.1; P = .04) or CM (difference, -1.7; 95% CI, -3.3 to -0.2; P = .03). Regarding depression, no significant differences were found. In contrast, GPT was superior to CM for all visits in the Clinical Global Impression global assessment of effectiveness. CONCLUSION AND RELEVANCE Highly structured group intervention did not outperform individual CM with regard to the primary outcome. Psychological interventions resulted in better outcomes during a 1-year period when combined with methylphenidate as compared with placebo."],["dc.description.sponsorship","German Federal Ministry of Education and Research [01GV0605, 01GV0606]"],["dc.identifier.doi","10.1001/jamapsychiatry.2015.2146"],["dc.identifier.isi","000367582200012"],["dc.identifier.pmid","26536057"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35232"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Medical Assoc"],["dc.relation.issn","2168-6238"],["dc.relation.issn","2168-622X"],["dc.title","Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder A Randomized Clinical Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Pharmacology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Hessmann, Philipp"],["dc.contributor.author","Zeidler, Jan"],["dc.contributor.author","Stahmeyer, Jona"],["dc.contributor.author","Eberhard, Sveja"],["dc.contributor.author","Vogelgsang, Jonathan"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Kis, Bernhard"],["dc.date.accessioned","2020-12-10T18:44:36Z"],["dc.date.available","2020-12-10T18:44:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3389/fphar.2019.00841"],["dc.identifier.eissn","1663-9812"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16751"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78524"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Claims Data Analysis on the Dispensing of Tricyclic Antidepressants Among Patients With Dementia in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Alzheimer's Disease"],["dc.bibliographiccitation.lastpage","13"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Schneider, Anja"],["dc.contributor.author","Belz, Michael"],["dc.date.accessioned","2022-12-01T08:31:30Z"],["dc.date.available","2022-12-01T08:31:30Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: The multimodal CORDIAL treatment concept for mild dementia, combining cognitive rehabilitation, cognitive behavioral and humanistic psychology interventions, has proven its feasibility and demonstrated a reduction of depressive symptoms in individual dyadic/triadic settings. Objective: We investigate antidepressant effects of an adapted group-based CORDIAL program in clinical routine care. Methods: During 2013 and 2017, 51 outpatients with mild dementia (45% female, mean age 72.4 years, 67% Alzheimer’s dementia, mean MMST 24.8) periodically received a modified CORDIAL group treatment as part of our regular outpatient care. Treatment comprised 10 bi-weekly sessions, partly involving caregivers. Systematic pre- and post-treatment assessments of clinical routine data were evaluated retrospectively (median time-interval of 6.6 months). Results: Depressive symptoms as measured by the Geriatric Depression Scale significantly decreased over time (p = 0.007, Cohen’s d = 0.39), and irrespective of gender. Patients with longer disease duration before treatment start showed significantly higher initial levels of depressive symptoms (p = 0.044), followed by a reduction to a level of those with shorter disease duration (ns). Most secondary outcomes (cognitive symptoms, disease severity, quality of life, caregiver burden) remained unchanged (ns), while competence in activities of daily living declined from pre- to post-measurement (p = 0.033). Conclusion: A group-based CORDIAL treatment is feasible in a clinical routine setting and demonstrated antidepressant effects comparable to those of the individual treatment design, further suggesting its implementation in regular care. Future trials might also investigate its potentially preventive effects by reducing depressive symptoms in pre-dementia stages, even at a subsyndromal level."],["dc.identifier.doi","10.3233/JAD-220578"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118184"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1875-8908"],["dc.relation.issn","1387-2877"],["dc.title","Antidepressant Effects of a Multimodal Group Therapy Program for Mild Dementia: A Retrospective Evaluation of Clinical Routine Data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1705"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Current Psychology"],["dc.bibliographiccitation.lastpage","1714"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Basilowski, M."],["dc.contributor.author","Schönfeld, B."],["dc.contributor.author","Esser, S."],["dc.contributor.author","Jatho, A."],["dc.contributor.author","Kownatka, M."],["dc.contributor.author","Signerski-Krieger, J."],["dc.contributor.author","Esselmann, H."],["dc.contributor.author","Grabemann, M."],["dc.contributor.author","Mette, C."],["dc.contributor.author","Strunz, L."],["dc.contributor.author","Zimmermann, M."],["dc.contributor.author","Lajcsak, E."],["dc.contributor.author","Scherbaum, N."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Kis, B."],["dc.contributor.author","Abdel-Hamid, M."],["dc.date.accessioned","2021-04-14T08:23:33Z"],["dc.date.available","2021-04-14T08:23:33Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s12144-018-9868-9"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80961"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1936-4733"],["dc.relation.issn","1046-1310"],["dc.title","From Bones to Brain: 50 Years of Star Trek and Changes in the Stigmatization of Psychological Disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S386"],["dc.bibliographiccitation.issue","S1"],["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.lastpage","S386"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Abdel-Hamid, M."],["dc.contributor.author","Tretbar, K."],["dc.contributor.author","Grabemann, M."],["dc.contributor.author","Meyer-Rötz, S."],["dc.contributor.author","Scherbaum, N."],["dc.contributor.author","Jens, W."],["dc.contributor.author","Kis, B."],["dc.date.accessioned","2020-12-10T14:23:58Z"],["dc.date.available","2020-12-10T14:23:58Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.eurpsy.2016.01.1388"],["dc.identifier.eissn","1778-3585"],["dc.identifier.issn","0924-9338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72090"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Mental health and hearing impairment - A German survey"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Hessmann, Philipp"],["dc.contributor.author","Schmidt, Ulrike"],["dc.contributor.author","Vogelgsang, Jonathan"],["dc.contributor.author","Ruhleder, Mirjana"],["dc.contributor.author","Kratzenberg, Alexander"],["dc.contributor.author","Treptow, Marit"],["dc.contributor.author","Reh-Bergen, Thorgund"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Heß, Luisa"],["dc.contributor.author","Belz, Michael"],["dc.date.accessioned","2021-12-01T09:22:58Z"],["dc.date.available","2021-12-01T09:22:58Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract While the COVID-19 pandemic continues, patients with pre-existing mental disorders are increasingly recognized as a risk group for adverse outcomes. However, data are conflicting and cover only short time spans so far. Here, we investigate the medium-term and peri-lockdown-related changes of mental health outcomes in such patients in a longitudinal study. A cohort of 159 patients comprising all major mental disorders (ICD-10 F0-F9) were interviewed twice with the Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) to evaluate psychosocial burden, psychiatric symptoms and resilience at the end of the first (April/May 2020) and the second lockdown in Germany (November/December 2020). For the primary outcome “psychosocial burden” ratings also comprised retrospective pre-pandemic (early 2020) and very early states during the pandemic (March 2020). For all diagnostic groups, psychosocial burden varied significantly over time ( p  < 0.001) with an increase from the pre-pandemic to the initial phase ( p  < 0.001), followed by a steady decrease across both lockdowns, normalizing in November/December 2020. Female gender, high adjustment disorder symptom load at baseline and psychiatric comorbidities were risk factors for higher levels and an unfavorable course of psychosocial burden. Most psychiatric symptoms changed minimally, while resilience decreased over time ( p  = 0.044 and p  = 0.037). The longitudinal course of psychosocial burden indicates an initial stress response, followed by a return to pre-pandemic levels even under recurrent lockdown conditions, mimicking symptoms of an adjustment disorder. Strategies for proactive, specific and continuous treatment have to address resilience capacities before their depletion in the pandemic aftermath, especially for patients with additional risk factors."],["dc.description.abstract","Abstract While the COVID-19 pandemic continues, patients with pre-existing mental disorders are increasingly recognized as a risk group for adverse outcomes. However, data are conflicting and cover only short time spans so far. Here, we investigate the medium-term and peri-lockdown-related changes of mental health outcomes in such patients in a longitudinal study. A cohort of 159 patients comprising all major mental disorders (ICD-10 F0-F9) were interviewed twice with the Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) to evaluate psychosocial burden, psychiatric symptoms and resilience at the end of the first (April/May 2020) and the second lockdown in Germany (November/December 2020). For the primary outcome “psychosocial burden” ratings also comprised retrospective pre-pandemic (early 2020) and very early states during the pandemic (March 2020). For all diagnostic groups, psychosocial burden varied significantly over time ( p  < 0.001) with an increase from the pre-pandemic to the initial phase ( p  < 0.001), followed by a steady decrease across both lockdowns, normalizing in November/December 2020. Female gender, high adjustment disorder symptom load at baseline and psychiatric comorbidities were risk factors for higher levels and an unfavorable course of psychosocial burden. Most psychiatric symptoms changed minimally, while resilience decreased over time ( p  = 0.044 and p  = 0.037). The longitudinal course of psychosocial burden indicates an initial stress response, followed by a return to pre-pandemic levels even under recurrent lockdown conditions, mimicking symptoms of an adjustment disorder. Strategies for proactive, specific and continuous treatment have to address resilience capacities before their depletion in the pandemic aftermath, especially for patients with additional risk factors."],["dc.identifier.doi","10.1007/s00406-021-01351-y"],["dc.identifier.pii","1351"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94526"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","506"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Acta Psychiatrica Scandinavica"],["dc.bibliographiccitation.lastpage","514"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Kis, B."],["dc.contributor.author","Guberina, N."],["dc.contributor.author","Kraemer, M."],["dc.contributor.author","Niklewski, F."],["dc.contributor.author","Dziobek, I."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Abdel-Hamid, M."],["dc.date.accessioned","2020-12-10T18:26:43Z"],["dc.date.available","2020-12-10T18:26:43Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/acps.12719"],["dc.identifier.issn","0001-690X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76162"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Perception of emotional prosody in adults with attention deficit hyperactivity disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e01401"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Brain and Behavior"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Abdel‐Hamid, Mona"],["dc.contributor.author","Niklewski, Franziska"],["dc.contributor.author","Heßmann, Philipp"],["dc.contributor.author","Guberina, Nika"],["dc.contributor.author","Kownatka, Melanie"],["dc.contributor.author","Kraemer, Markus"],["dc.contributor.author","Scherbaum, Norbert"],["dc.contributor.author","Dziobek, Isabel"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Kis, Bernhard"],["dc.date.accessioned","2019-12-02T10:36:20Z"],["dc.date.accessioned","2021-10-27T13:21:41Z"],["dc.date.available","2019-12-02T10:36:20Z"],["dc.date.available","2021-10-27T13:21:41Z"],["dc.date.issued","2019"],["dc.description.abstract","OBJECTIVE: The cognitive capacity to change perspective is referred to as theory of mind (ToM). ToM deficits are detectable in a variety of psychiatric and neurological disorders. Since executive abilities are closely associated with ToM skills, we suspected that due to a common neuropsychological basis, ToM deficits exist in treatment-naïve adults with attention-deficit/hyperactivity disorder (ADHD). METHODS: Performance of treatment-naïve adults with ADHD (N = 30) in tasks assessing executive functions (Trail Making Test, Stroop color-word test, and Test Battery for Attentional Performance), empathy skills (Cambridge Behaviour Scale), and ToM (Movie for Assessment of Social Cognition) was compared with that of a healthy control group (N = 30) matched according to basic demographic variables. RESULTS: Compared to healthy controls, treatment-naïve adults with ADHD showed deficits in various executive functions and the ability to empathize (all p < .05). However, no performance differences were found with regard to ToM (all n.s.). CONCLUSIONS: Since studies in juveniles with ADHD often show impaired ToM performance, it is conceivable that ToM deficits may become attenuated due to neuronal development in adolescence. Furthermore, our findings imply that ToM impairments, even when present in adult ADHD, appear to be independent of executive deficits and might be explained by comorbid disorders."],["dc.identifier.doi","10.1002/brb3.1401"],["dc.identifier.eissn","2162-3279"],["dc.identifier.issn","2162-3279"],["dc.identifier.pmid","31475781"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16781"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92040"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","2162-3279"],["dc.relation.issn","2162-3279"],["dc.relation.issn","2162-3279"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Impaired empathy but no theory of mind deficits in adult attention deficit hyperactivity disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","282"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Clinical Psychopharmacology"],["dc.bibliographiccitation.lastpage","289"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Hessmann, Philipp"],["dc.contributor.author","Zeidler, Jan"],["dc.contributor.author","Neubauer, Sarah"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Stahmeyer, Jona"],["dc.contributor.author","Eberhard, Sveja"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Kis, Bernhard"],["dc.date.accessioned","2020-12-10T18:20:15Z"],["dc.date.available","2020-12-10T18:20:15Z"],["dc.date.issued","2018"],["dc.description.abstract","Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 and 2015, including patients with an incident diagnosis of dementia in 2014. The aim was to evaluate the continuity of treatment, the frequency of BZD prescriptions and defined daily doses were evaluated. In total, 1298 (5.6%) patients received 4.7±5.2 BZD prescriptions in 2015 on average. Thereof, lorazepam (47.5%), oxazepam (18.6%), diazepam (14.5%), and bromazepam (12.2%) were most often prescribed. 30.7% of the patients received at least one BZD prescription in each quarter of 2015. Although the total number of patients receiving BZD decreased in 2015, defined daily doses for single substances remained mainly unchanged. The incident diagnosis of dementia was not associated with modifications of prescription behavior. The treatment with BZD was not discontinued in a large proportion of dementia patients, increasing the risk of adverse events. Physicians' awareness of avoiding BZD should be improved and further evidence for the appropriate treatment of psychiatric symptoms in dementia (e.g. sleep disturbances, anxiety) is required."],["dc.identifier.doi","10.1097/YIC.0000000000000230"],["dc.identifier.issn","0268-1315"],["dc.identifier.pmid","29952800"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75497"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","final"],["dc.relation.eissn","1473-5857"],["dc.title","Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e194980"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","JAMA Network Open"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Lam, Alexandra P."],["dc.contributor.author","Matthies, Swantje"],["dc.contributor.author","Graf, Erika"],["dc.contributor.author","Colla, Michael"],["dc.contributor.author","Jacob, Christian"],["dc.contributor.author","Sobanski, Esther"],["dc.contributor.author","Alm, Barbara"],["dc.contributor.author","Rösler, Michael"],["dc.contributor.author","Retz, Wolfgang"],["dc.contributor.author","Retz-Junginger, Petra"],["dc.contributor.author","Kis, Bernhard"],["dc.contributor.author","Abdel-Hamid, Mona"],["dc.contributor.author","Müller, Helge H. O."],["dc.contributor.author","Lücke, Caroline"],["dc.contributor.author","Huss, Michael"],["dc.contributor.author","Jans, Thomas"],["dc.contributor.author","Berger, Mathias"],["dc.contributor.author","Tebartz van Elst, Ludger"],["dc.contributor.author","Philipsen, Alexandra"],["dc.date.accessioned","2020-12-10T14:05:30Z"],["dc.date.available","2020-12-10T14:05:30Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1001/jamanetworkopen.2019.4980"],["dc.identifier.eissn","2574-3805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69561"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms"],["dc.title.alternative","Follow-up Analysis of the COMPAS Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]